DelveInsight's "HER2+ Gastric Cancer - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted HER2+ Gastric Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The DelveInsight HER2+ Gastric Cancer epidemiology report gives a thorough understanding of the HER2+ Gastric Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for HER2+ Gastric Cancer in the US, Europe, and Japan. The report covers the detailed information of the HER2+ Gastric Cancer epidemiology scenario in seven major countries (US, EU5, and Japan).
The HER2+ Gastric Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The HER2+ Gastric Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The HER2+ Gastric Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The HER2+ Gastric Cancer epidemiology covered in the report provides historical as well as forecasted HER2+ Gastric Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The DelveInsight HER2+ Gastric Cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
The HER2+ Gastric Cancer Epidemiology report will allow the user to -
1. Key Insights
2. Executive Summary of HER2+ Gastric Cancer
3. HER2+ Gastric Cancer: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. HER2+ Gastric Cancer Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. HER2+ Gastric Cancer Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. HER2+ Gastric Cancer Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. HER2+ Gastric Cancer Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. HER2+ Gastric Cancer Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. HER2+ Gastric Cancer Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. HER2+ Gastric Cancer Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. HER2+ Gastric Cancer Epidemiology Scenario in Japan (2019- 2032)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. HER2+ Gastric Cancer Treatment and Management
6.2. HER2+ Gastric Cancer Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
List of Tables
Table 1: HER2+ Gastric Cancer Epidemiology in 7MM (2019-2032)
Table 2: HER2+ Gastric Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: HER2+ Gastric Cancer Epidemiology in the United States (2019-2032)
Table 4: HER2+ Gastric Cancer Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: HER2+ Gastric Cancer Epidemiology in Germany (2019-2032)
Table 6: HER2+ Gastric Cancer Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: HER2+ Gastric Cancer Epidemiology in France (2019-2032)
Table 8: HER2+ Gastric Cancer Diagnosed and Treatable Cases in France (2019-2032)
Table 9: HER2+ Gastric Cancer Epidemiology in Italy (2019-2032)
Table 10: HER2+ Gastric Cancer Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: HER2+ Gastric Cancer Epidemiology in Spain (2019-2032)
Table 12: HER2+ Gastric Cancer Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: HER2+ Gastric Cancer Epidemiology in the United Kingdom (2019-2032)
Table 14: HER2+ Gastric Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: HER2+ Gastric Cancer Epidemiology in Japan (2019-2032)
Table 16: HER2+ Gastric Cancer Diagnosed and Treatable Cases in Japan (2019-2032)
List of Figures
Figure 1 HER2+ Gastric Cancer Epidemiology in 7MM (2019-2032)
Figure 2 HER2+ Gastric Cancer Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 HER2+ Gastric Cancer Epidemiology in the United States (2019-2032)
Figure 4 HER2+ Gastric Cancer Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 HER2+ Gastric Cancer Epidemiology in Germany (2019-2032)
Figure 6 HER2+ Gastric Cancer Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 HER2+ Gastric Cancer Epidemiology in France (2019-2032)
Figure 8 HER2+ Gastric Cancer Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 HER2+ Gastric Cancer Epidemiology in Italy (2019-2032)
Figure 10 HER2+ Gastric Cancer Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 HER2+ Gastric Cancer Epidemiology in Spain (2019-2032)
Figure 12 HER2+ Gastric Cancer Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 HER2+ Gastric Cancer Epidemiology in the United Kingdom (2019-2032)
Figure 14 HER2+ Gastric Cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 HER2+ Gastric Cancer Epidemiology in Japan (2019-2032)
Figure 16 HER2+ Gastric Cancer Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report